Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
bioMerieux ( (FR:BIM) ) has issued an announcement.
bioMérieux has launched GENE-UP® TYPER, an innovative real-time PCR diagnostic solution designed to rapidly analyze the origin of Listeria monocytogenes contaminations in the food industry. This launch addresses significant health and financial issues related to food contamination by enabling rapid identification and decision-making, thus helping food producers prevent future contaminations. By collaborating with Mérieux NutriSciences, bioMérieux aims to enhance global food safety standards and ensure the solution’s availability worldwide, marking a significant advancement in pathogen detection and contamination control.
More about bioMerieux
bioMérieux is a global leader in the in vitro diagnostics industry, founded in 1963 and operating in 45 countries with a presence in over 160 countries through a vast network of distributors. The company specializes in providing diagnostic solutions, including systems, reagents, software, and services, primarily for diagnosing infectious diseases and detecting microorganisms in food, pharmaceutical, and cosmetic products. In 2023, bioMérieux achieved sales of 3.7 billion euros, with over 90% of revenue generated internationally.
YTD Price Performance: 12.23%
Average Trading Volume: 38,000
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €13.59B
For a thorough assessment of BIM stock, go to TipRanks’ Stock Analysis page.
